A New Platform Adhesive Technology
Strong. Resorbable. Biocompatible.
Cohera Medical’s patented technology platform is a lysine-derived urethane adhesive with a unique chemical composition that cures in the presence of moisture. The technology is resorbable, biocompatible for internal use, uses no human or animal based ingredients and forms a bond five times stronger than any other product on the market indicated for adhesion of soft tissue layers inside the body.
Researchers at Cohera Medical have developed this platform technology to serve the needs of surgeons in multiple disciplines who have long sought a simple to use adhesive that is strong enough to hold tissues together yet is biocompatible and not associated with foreign body adverse tissue responses.
Holds tissues together to facilitate natural healing processes
Cohera Medical’s adhesive technology has shown shear strength that is similar to external adhesives and forms a bond that has five times the holding strength of fibrin-based sealants.
No introduction of animal or human ingredients
Cohera’s Medical’s technology is fully synthetic. This biocompatible adhesive platform is composed of lysine, an essential amino-acid, and a biocompatible urethane polymer unlike any on the market today.
Tissues heal naturally
The adhesive holds tissues together as the natural healing process occurs and is then resorbed by the body after degrading into harmless subcomponents.
Not associated with foreign body response
Non-toxic and biocompatible for internal use.
Save time in the operating room
The adhesive technology is synthesized as a single component that stores at room temperature, requires no mixing and is designed for rapid treatment using simple, single-use applicators.
Small changes in the platform’s chemical formulation can lead to product line extensions for a variety of surgical indications, including soft tissue fixation, bowel sealants, mesh fixation, and small bone approximation.
Our first commercial product, TissuGlu® Surgical Adhesive*, is an adhesive for internal use which secures planar flaps of tissue in order to reduce fluid accumulation in the wound following abdominoplasty (tummy tuck) and other plastic surgery procedures. It is indicated in the European market for the approximation of tissue layers where subcutaneous deadspace exists between the tissue planes in large flap surgical procedures such as abdominoplasty.*
Cohera Medical researchers are currently developing Sylys® Surgical Sealant, which is designed for colonic and small bowel anastomoses. Other areas of clinical investigation include development of a fast-curing, strong adhesive for securing soft tissues and implantable devices such as surgical mesh for hernia fixation and gynecologic procedures.†
*Disclaimer: TissuGlu Surgical Adhesive received European CE Mark in 2011. Currently, TissuGlu Surgical Adhesive is approved for investigational use only in the United States and is not approved for sale or marketing in the U.S. or any other country outside of the EU.
†Disclaimer: These products are not currently available for sale or distribution and have not been approved by the U.S. FDA or any other country’s regulatory authority. The devices described are currently limited to non-human investigational use only.